{"id":972854,"date":"2026-06-16T17:07:27","date_gmt":"2026-06-16T21:07:27","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/jazz-pharmaceuticals-delivers-extensive-late-breaking-data-at-sleep-2026-demonstrating-real-world-impact-of-xywav-calcium-magnesium-potassium-and-sodium-oxybates-on-patient-outcomes-across\/"},"modified":"2026-06-16T17:07:27","modified_gmt":"2026-06-16T21:07:27","slug":"jazz-pharmaceuticals-delivers-extensive-late-breaking-data-at-sleep-2026-demonstrating-real-world-impact-of-xywav-calcium-magnesium-potassium-and-sodium-oxybates-on-patient-outcomes-across","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/jazz-pharmaceuticals-delivers-extensive-late-breaking-data-at-sleep-2026-demonstrating-real-world-impact-of-xywav-calcium-magnesium-potassium-and-sodium-oxybates-on-patient-outcomes-across\/","title":{"rendered":"Jazz Pharmaceuticals Delivers Extensive Late-Breaking Data at SLEEP 2026, Demonstrating Real-World Impact of Xywav\u00ae (calcium, magnesium, potassium, and sodium oxybates) on Patient Outcomes Across Narcolepsy and Idiopathic Hypersomnia"},"content":{"rendered":"
\n

PR Newswire<\/p>\n<\/p><\/div>\n

\n

\n New late-breaking data presentations underscore Jazz’s significant progress in advancing holistic understanding of narcolepsy and idiopathic hypersomnia, including novel real-world evidence of meaningful changes in cardiometabolic risk markers following Xywav initiation<\/i>\n <\/p>\n

\n For U.S. media and investors only<\/i>\n <\/p>\n

\n DUBLIN<\/span>, June 16, 2026<\/span> \/PRNewswire\/ — Jazz Pharmaceuticals plc\u00a0(Nasdaq: JAZZ) today announced 11 late-breaking presentations at SLEEP 2026, including notable new research showcasing the comprehensive treatment outcomes of Xywav\u00ae<\/sup>\u00a0(calcium, magnesium, potassium, and sodium oxybates) oral solution in patients with narcolepsy and idiopathic hypersomnia (IH). These late-breaking presentations advance scientific understanding of individualized dosing regimens and the broader cardiometabolic impacts of reduced sodium exposure in patients living with these debilitating conditions.<\/p>\n

“Treating rare sleep conditions like narcolepsy and idiopathic hypersomnia requires a holistic approach that extends beyond immediate symptoms. Because these patients face greater cardiovascular risk, managing sodium intake is a critical component of their care,” said Logan Schneider, M.D., adjunct clinical associate professor of sleep medicine, Stanford Sleep Center and Consultant Neurologist, Stanford\/VA Alzheimer’s Center. “These new data from Jazz continue to build on our understanding of the relationship between sleep architecture and patient-reported sleep and improvements in patient-reported daytime symptoms, as well as how sodium reduction directly impacts patient well-being and considerations when personalizing therapy.”<\/p>\n

“The breadth and rigor of the evidence we are presenting at SLEEP 2026 reflects years of dedicated scientific inquiry into narcolepsy and idiopathic hypersomnia,” said\u00a0Jessa Alexander, Ph.D., neuroscience therapeutic area head, global medical and scientific affairs of\u00a0Jazz Pharmaceuticals. “Jazz is advancing the scientific understanding of these rare sleep conditions with novel data which demonstrates the potential of Xywav’s <\/i>individualized dosing optimization and the impact of its low-sodium formulation within the context of elevated cardiovascular and cardiometabolic risk. Our research is illuminating the transformative potential of Xywav <\/i>to deliver outcomes which shape treatment paradigms and have the potential to improve the quality of life for patients living with these conditions.”<\/p>\n

Key findings from these late-breaking presentations provide insights into the complex landscape of sleep disorders, across key areas such as:<\/p>\n

\n
\n Xywav<\/i>
\n <\/b>
\n Individualized Dosing Supports Personalized Treatment Regimens (P-41, Posters #528 and #529)
<\/b>New analyses demonstrate that the individualized dosing regimens Xywav <\/i>allows can be uniquely tailored for patients with narcolepsy or IH. A post-hoc analysis from the Phase 4, prospective, single-arm, open-label DUET (Develop hypersomnia\u00a0Understanding by\u00a0Evaluating low-sodium oxybate\u00a0Treatment) study shows how incremental dose adjustments can yield a variety of once- or twice-nightly regimens based on efficacy and tolerability of the individual patient. Within the study cohorts, the mean (range) time to reach a stable dose was 42.1 (14-62) days for idiopathic hypersomnia and 41.8 (12-67) days for narcolepsy. Reinforcing the real-world applicability of this approach, data from the Xywav<\/i> REMS program, which analyzed over 13,000 patients, demonstrated the feasibility of individualized, patient-centered care enabled by Xywav’s<\/i> oral solution formulation when clinically warranted.<\/p>\n

\n Xywav<\/i>\u00a0is the only low-sodium oxybate approved by the\u00a0U.S. Food and Drug Administration\u00a0for the treatment of cataplexy or excessive daytime sleepiness (EDS) in patients 7 years of age and older with narcolepsy and for the treatment of IH in adults. The\u00a0Xywav<\/i>\u00a0label recommends a nightly dosage of 6-9 grams per night.<\/p>\n

\n The Impact of a Low-Sodium Formulation Option on Long-Term Cardiometabolic Health (P-41, Posters #526 and #527)
<\/b>New data showcases that Xywav’s<\/i> low-sodium formulation extended health benefits beyond the core symptoms of narcolepsy and IH, offering meaningful health gains for patients managing the long-term consequences of these conditions. Secondary results from the open-label, single-arm Phase 4 XYLO study indicate that patients with narcolepsy who switched from high-sodium oxybate to Xywav<\/i> reported qualitative improvements in symptoms associated with sodium\/fluid imbalance, such as edema, diaphoresis, and nocturia, highlighting the clinical benefits of lowering sodium exposure. Moreover, a novel retrospective analysis using electronic health records showed decreases in lipid biomarkers associated with cardiovascular\/cardiometabolic (CV\/CM) risk, including non-high-density lipoprotein (HDL) cholesterol and triglycerides after Xywav<\/i> initiation, suggesting risk mitigation for CV\/CM outcomes in this patient population. Notably, among the subset of patients with baseline high-sodium oxybate use, initiation of Xywav <\/i>was associated with additional CM benefits, including a decrease in office-based systolic blood pressure and an increase in HDL cholesterol.<\/p>\n

The\u00a0full abstracts will be available\u00a0online\u00a0at: sleepmeeting.org\/abstract-supplements<\/a><\/p>\n

\n About Narcolepsy<\/b>
\n
Narcolepsy is a chronic, debilitating neurologic sleep disorder characterized by the inability to\u00a0maintain\u00a0continuous sleep at night and sustained wakefulness throughout the day. This leads to symptoms that can include fragmented or disrupted nighttime sleep, excessive daytime sleepiness, and cataplexy.1<\/sup>\u00a0Patients with narcolepsy experience severe excessive daytime sleepiness that can manifest as sleep attacks and, despite fighting the urge to sleep, may unintentionally fall asleep for short periods.2,3<\/sup>\u202fThese sleep attacks may happen at inappropriate or potentially dangerous times such as during driving, cycling, eating, or mid-conversation.4<\/sup>\u00a0<\/p>\n

There is no cure for narcolepsy;\u00a0the symptoms are\u00a0lifelong and\u00a0have\u00a0a substantial negative impact on a person’s ability to function psychologically, socially and professionally.5<\/sup>\u202fPatients with narcolepsy are at increased risk for\u202fhypertension, cardiometabolic morbidity,\u202fstroke, myocardial infarction, heart failure, cardiac arrest, and death.6,7,8,9<\/sup>\u00a0As narcolepsy is a chronic condition that requires lifelong treatment,\u00a0early access to an effective treatment can help reduce the impact of narcolepsy symptoms on a person’s physical and mental health, and long-term impacts of the treatment\u00a0on\u00a0cardiovascular health should be considered.5<\/sup>\u00a0<\/p>\n

\n About Idiopathic Hypersomnia\u202f<\/b>\u00a0
Idiopathic hypersomnia (IH) is a debilitating, neurologic sleep disorder that goes beyond chronic excessive daytime sleepiness.10,11,12,13<\/sup>\u202fIdiopathic hypersomnia is a 24-hour sleep disorder, and symptoms may include non-restorative\u00a0sleep with or without long sleep time\u00a0(main,\u00a0nighttime,\u00a0sleep episode of more than 9 hours, or a sleep duration of 11 hours or longer over a 24-hour period); severe sleep inertia (prolonged difficulty waking, with frequent reentries into sleep, confusion, and irritability);\u00a0long and unrefreshing naps;\u00a0cognitive impairment\u00a0and\u00a0brain fog, or the inability to focus for long periods of time.10,11,12,13,14\u202f<\/sup>Although there are\u00a0some\u00a0overlapping clinical features with narcolepsy, idiopathic hypersomnia is a condition with its own specific diagnostic criteria.13,15<\/sup>\u202f\u00a0<\/p>\n

Idiopathic hypersomnia is an often debilitating illness that can significantly affect social, educational, and occupational functioning.16,17<\/sup>\u00a0In the\u00a0U.S., approximately 28,000 adult patients are diagnosed with idiopathic hypersomnia annually and are actively seeking healthcare, with the diagnosed prevalence continuing to rise year over year.18<\/sup>\u00a0This low number of people may be due to the many difficulties in identifying and diagnosing idiopathic hypersomnia, as well as distinguishing it from other similar sleep disorders. It is estimated that far fewer patients are currently receiving pharmacological treatment for their idiopathic hypersomnia.19,20,21<\/sup>\u00a0<\/p>\n

\n About Xywav<\/b>
\n
\n \u00ae<\/sup>
\n <\/b>\u00a0(calcium, magnesium, potassium, and sodium oxybates) oral solution<\/b>
Xywav<\/i>\u00a0is the only low-sodium oxybate approved by the\u00a0U.S. Food and Drug Administration\u00a0(FDA) for the treatment of cataplexy or excessive daytime sleepiness (EDS) in patients 7 years of age and older with narcolepsy. The FDA recognized seven years of Orphan Drug Exclusivity for\u00a0Xywav<\/i>\u00a0for the treatment of cataplexy or EDS in patients 7 years of age and older with narcolepsy. The Office of Orphan Product Development (OOPD) at the FDA also published its summary of clinical superiority findings for\u00a0Xywav<\/i>\u00a0for the treatment of cataplexy or EDS in patients 7 years of age and older with narcolepsy by means of greater cardiovascular safety compared to Xyrem\u00ae<\/sup>\u00a0(sodium oxybate) oral solution. The decision of the OOPD is based on the FDA findings that\u00a0Xywav<\/i>\u00a0provides a greatly reduced chronic sodium burden compared to\u00a0Xyrem<\/i>.\u00a0Xywav<\/i>\u00a0has 131 mg of sodium at the maximum recommended nightly dose\u00a0whereas other high sodium oxybates have 1640 mg at the equivalent dose.\u00a0Xywav<\/i>\u00a0is comprised of a unique composition of cations resulting in 92% less sodium, or a reduction of approximately 1,000 to 1,500 mg\/night at the recommended dose range of 6 g to 9 g\/night.\u00a0Xywav<\/i>\u00a0is the only oxybate therapy that does not carry a warning in the label related to use in patients sensitive to high sodium intake.<\/p>\n

\n Xywav<\/i>\u00a0is also the first and only\u00a0U.S.\u00a0FDA-approved treatment option for idiopathic hypersomnia in adults. The FDA recognized seven years of Orphan Drug Exclusivity for\u00a0Xywav<\/i>\u00a0for the treatment of idiopathic hypersomnia in adults.\u00a0Xywav<\/i>\u00a0is the only FDA-approved treatment studied across the multiple symptoms of idiopathic hypersomnia, such as EDS, sleep inertia (severe grogginess or confusion when waking up), long sleep duration and cognitive impairment.\u00a0Xywav<\/i>\u00a0can be administered as a twice- or once-nightly regimen for the treatment of idiopathic hypersomnia in adults.<\/p>\n

The exact mechanism of action of\u00a0Xywav<\/i>\u00a0in the treatment of adults with idiopathic hypersomnia and of cataplexy and EDS in narcolepsy is unknown. It is hypothesized that the therapeutic effects of\u00a0Xywav<\/i>\u00a0are mediated through GABAB<\/sub>\u00a0actions during sleep at noradrenergic and dopaminergic neurons, as well as thalamocortical neurons.22<\/sup>\u00a0The\u00a0U.S.\u00a0Drug Enforcement Agency\u00a0(DEA) has designated\u00a0Xywav<\/i>\u00a0as a Schedule III medicine. The DEA defines Schedule III drugs, substances, or chemicals as drugs with a moderate to low potential for physical and psychological dependence.22,23<\/sup>\u00a0Because of the risks of central nervous system (CNS) depression and abuse and misuse,\u00a0Xywav<\/i>\u00a0is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) called the XYWAV and XYREM REMS.<\/p>\n

\n Important Safety Information for Xywav<\/b>\n <\/p>\n

\n\n\n
\n

\n
\n WARNING: CENTRAL NERVOUS SYSTEM DEPRESSION and ABUSE AND MISUSE.<\/b>
\n <\/span>\n <\/p>\n